ESTRO 37 Abstract book

S837

ESTRO 37

Material and Methods Retrospective comparative study of 460 pts with PC treated with EBRT+ADT with PSA level ≤0.1ng/ml (82 pts) vs >0.1ng/ml (378 pts) after 1-6 months of EBRT in our hospitals from October 2001 to December 2011. Baseline characteristics differed significantly between treatment groups in PSA level, risk group, percentage of positive cylinder, ADT duration, pelvis RT and total dose of RT. All pts were treated with 3DCRT at a median total dose of 78 Gy (range 60-78). Phoenix definition was used for biochemical failure. Survival rates were estimated with Kaplan-Meier and compared with Log Rank test. Prognostic factors such as age, primary tumour stage, Risk group, Gleason, percentage of positive cylinder, radiotherapy total dose and ADT duration have been related to BDFS, OS and CSS using Cox regression. Results The median follow-up was 98.48 months (range 16-235) in PSA level ≤0.1ng/ml pts and 89,93 months (range 24-155) in >0.1ng/ml (p=0.001). The 8-year BDFS, OS and CSS in PSA≤0.1ng/ml pts were 89.7%, 84.8%, and 97.9% respectively and in PSA>0.1ng/ml were 71.1% (p=0.000), 70.8% (p=0.001), and 85.9% (p=0.000) respectively. In the multivariate analysis, PSA level ≤0.1ng/ml was a significant prognostic factor of BDFS, OS and CSS. Conclusion Regarding to our results, prostate cancer patients with PSA level ≤0.1ng/ml after EBRT+ADT have significantly higher BDFS, OS and CCS than patients with PSA level >0.1ng/ml. PSA ≤0.1ng/ml after RT+ADT should be considered as a prognostic factor of treatment results with implications in treatment decisions. J.L. Munoz Garcia 1 , M.F. Ropero Carmona 2 , M.C. Cruz Muñoz 2 , M.A. Gonzalez Ruiz 2 , P. Simon Silva 2 , J. Quiros Rivero 3 , Y. Rios Kavadoy 2 , A. Corbacho Campos 2 , J.J. Cabrera Rodriguez 2 1 Infanta Cristina Universitary Hospital, Oncologia Radiotherapia, Badajoz, Spain 2 Infanta Cristina Universitary Hospital, Badajoz, Spain 3 Infanta Cristina Universitary Hospital, Radiation Oncology, Badajoz, Spain Purpose or Objective Prostate irradiation is associated with an increased risk of second tumors (ST) that may occur decades after treatment. The aim of our study is to analyze ST after prostate cancer (PC) treatment in our institution. Material and Methods Retrospective analysis of 68 out of 460 patients (pts) who developed SM [(<36 months (20.6%), 36-66 months (30.9%), >60 months (48,5%)] in PC pts treated with radiotherapy (RT) plus androgen deprivation therapy (ADT) from October 2001 to December 2011. Median age was 71 years old (49-80). Most pts had tumor stage T2b- T2c, initial PSA >10 ng/ml, intermediate-high risk group, Gleason score<8, and long-lasting ADT>24 months. In addition most pts were non-smokers, non-alcoholics and non-obese. All patients were treated with 3DCRT (median total dose 78 Gy). Survival rates were estimated with Kaplan-Meier and compared with Log Rank test. Results 14.78% pts developed ST with a median follow-up of 92.25 months (range 31-175). The median time until ST appearance was 60 months (10-148). 17 (25%) of ST were inside pelvis with a median time of 94 months (57-134) and 51 (75%) outside pelvis with a median time of 92 EP-1548 Second tumors after treatment in prostate cancer patients

months (31-175). Colorectal cancer was the most common location (22%) followed by skin (19%), bladder (12%) and lung (12%). 9 year OS was 43%, 31% and 74% (p=0.000) in <36, 36-60 and >60 months ST respectively.Regarding our results colorectal cancer was the most frequent second tumor after prostate cancer treatment, followed by skin, bladder and lung. According to these results it would be advisable to perform a colonoscopy before treatment and give recommendations of health habits and sun protection. Conclusion Regarding our results colorectal cancer was the most frequent second tumor after prostate cancer treatment, followed by skin, bladder and lung. According to these results it would be advisable to perform a colonoscopy before treatment and give recommendations of health habits and sun protection. EP-1549 Lack of radioprotective efficacy of nanocurcumin in prostate cancer patients undergoing radiotherapy B. Mofid 1 , A. Razzaghdoust 2 , A. Sadipour 1 , M. Bakhshandeh 1 , A. Mahdavi 3 1 Shohada-e-Tajrish Hospital- Shahid Beheshti University of Medical Sciences, Radiation Oncology, Tehran, Iran Islamic Republic of 2 Urology and Nephrology Research Center- Shahid Beheshti University of Medical Sciences, Urology, Tehran, Iran Islamic Republic of 3 Shahid Modarres Hospital- Shahid Beheshti University of Medical Sciences, Radiology, Tehran, Iran Islamic Republic of Purpose or Objective There is a growing body of evidence exploring the role of high-dose curcumin as one of the most promising radioprotectors against radiation-induced toxicities in normal tissues as well as a radiosensitiser in tumor cells. Efficacy of oral curcumin is limited by poor absorption and, thus, its clinical application is hindered. Curcumin nanoformulation is considered as a novel promising approach to overcome low bioavailability of oral curcumin. The aim of this double-blind randomised placebo-controlled trial was to determine the efficacy of oral nanocurcumin in prostate cancer patients undergoing radiotherapy (RT). Material and Methods Between March 2016 and April 2017, 64 intermediate- or high-risk prostate cancer patients were randomised to receive either oral nanocurcumin or placebo three days before and during the RT course (120mg/day). The nanocurcumin 40mg or placebo capsules were taken three times daily, so two capsules were administered in the morning and another capsule at bedtime. All patients were stratified by treatment schedule and received either conventional fractionated (70Gy, 2Gy/fraction) or hypofractionated schedule (70.2Gy, 2.7Gy/fraction). All patients received neoadjuvant hormone therapy. An intention to treat approach was used as the analysis strategy. Acute toxicities were assessed weekly during the treatment and once thereafter according to CTCAE grading criteria. The patients are followed to evaluate the treatment response. Pearson’s chi-square and fisher’s exact test were used to compare the number of patients with acute toxicities in the two groups. The duration of acute toxicities was compared using Mann–Whitney U test. A p value <0.05 (two-sided test) was considered significant.